Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | 5,180 |
| Gross Profit (TTM) | $-6.72M |
| EBITDA | $-13.20M |
| Operating Margin | -255026.00% |
| Return on Equity | -46.20% |
| Return on Assets | -27.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.10 |
| Price-to-Book | 0.26 |
| Price-to-Sales (TTM) | 1928.86 |
| EV/Revenue | - |
| EV/EBITDA | 0.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -98.40% |
| Shares Outstanding | $12.59M |
| Float | $7.91M |
| % Insiders | 9.17% |
| % Institutions | 18.83% |
Volatility is currently expanding
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051 Enrollment in ACESOT-1051 is accelerating as the Company advances dose escalation and amasses the clinical data needed to inform dose selection and subsequent development Aprea plans to advance APR-1051 in uterine serous carcinoma (USC) and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head and neck cancer and colorectal cancer, utilizing dose levels that have shown single-agent activity and cleared safety review The expanded development strategy builds on emerging single-agent activity and positions APR-1051 across biomarker-defined indications where WEE1 inhibition may address significant unmet medical need DOYLESTOWN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on the ongoing Phase 1 dose escalation ACESOT-1051 trial of its oral WEE1 inhibitor APR-1051.
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027 DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” on May 30 at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, taking place in Chicago, Illinois.
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago, IL.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on APRE and any ticker you trade — then tracks every position and per-strategy win rate.
